Key result
Apple polyphenol extract rich in epicatechin did not significantly improve long-term or acute brachial artery flow-mediated vasodilatation compared to placebo in adults with borderline or mild hypertension.
Why the study?
Does an orally ingested apple polyphenol extract rich in epicatechin improve brachial artery flow-mediated vasodilatation in volunteers with borderline or mild hypertension?
RCT (n=60)
Double-blind
Cross-over
No
Does an orally ingested apple polyphenol extract rich in epicatechin improve brachial artery flow-mediated vasodilatation in volunteers with borderline or mild hypertension?
Absolute Event Rate: -0.7% vs -0.1%
p-value: p=0.449
Daily supplementation with an apple polyphenol extract rich in epicatechin did not significantly improve endothelial function compared to placebo in individuals with borderline or mild hypertension.
Does not support apple polyphenol extract for endothelial function in mild hypertension; challenges prior suggestions of flavanol benefit.
BACKGROUND: The primary aim of this study was to test the hypothesis that an orally ingested apple polyphenol extract rich in epicatechin and flavan-3-ol oligomers improves endothelium-dependent brachial artery flow-mediated vasodilatation (FMD) in volunteers with borderline hypertension. The secondary aim of the study was to test whether the investigational product would improve endothelium-independent nitrate-mediated vasodilatation (NMD). METHODS: This was a single centre, repeated-dose, double-blind, placebo-controlled, crossover study in 60 otherwise healthy subjects (26 men, 34 women; aged 40-65 years) with borderline hypertension (blood pressure 130-139/85-89 mmHg) or unmedicated mild hypertension (blood pressure 140-165/90-95 mmHg). The subjects were randomised to receive placebo or the apple polyphenol extract to provide a daily dose of 100 mg epicatechin for 4 weeks, followed by a four to five-week wash-out period, and then 4 weeks intake of the product that they did not receive during the first treatment period. FMD and NMD of the left brachial artery were investigated with ultrasonography at the start and end of both treatment periods, and the per cent increase of the arterial diameter (FMD% and NMD%) was calculated. RESULTS: With the apple extract treatment, a significant acute improvement was detected in the mean change of maximum FMD% at the first visit 1.16 (p = 0.04, 95% CI: 0.04; 2.28), last visit 1.37 (p = 0.02, 95% CI: 0.22; 2.52) and for both visits combined 1.29 (p < 0.01, 95% CI: 0.40; 2.18). However, such improvement was not statistically significant when apple extract was compared with placebo. The overall long-term effect of apple extract on FMD% was not different from placebo. No statistically significant differences between the apple extract and placebo treatments were observed for endothelium-independent NMD. CONCLUSIONS: A significant acute improvement in maximum FMD% with apple extract administration was found. However, superiority of apple extract over placebo was not statistically significant in our study subjects with borderline hypertension or mild hypertension. The study raised no safety concerns regarding the daily administration of an apple polyphenol extract rich in epicatechin. TRIAL REGISTRATION: The trial is registered at http://clinicaltrials.gov (identifier: NCT01690676 ). Registered 25th May 2012.
No takes yet. Share an insight, caveat, or question.
Saarenhovi et al. (2017) conducted an RCT in Borderline hypertension or unmedicated mild hypertension (n=60). Apple polyphenol extract rich in epicatechin and flavan-3-ol oligomers vs. Placebo was evaluated on Long-term change from baseline in maximal flow-mediated vasodilatation (FMD%) (p=0.449). Apple polyphenol extract rich in epicatechin did not significantly improve long-term or acute brachial artery flow-mediated vasodilatation compared to placebo in adults with borderline or mild hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: